Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.

Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.


Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.

Cell Death Dis. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406.


Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Falkenius J, Johansson H, Tuominen R, Frostvik Stolt M, Hansson J, Egyhazi Brage S.

BMC Cancer. 2017 Aug 29;17(1):584. doi: 10.1186/s12885-017-3577-x.


Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.

Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, Söderberg M, Walz TM, Fernö M, Hatschek T, Hedenfalk I; TEX study group.

Clin Cancer Res. 2016 Jan 1;22(1):146-57. doi: 10.1158/1078-0432.CCR-15-0487. Epub 2015 Aug 14.


MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S.

Int J Cancer. 2015 Jun 15;136(12):2844-53. doi: 10.1002/ijc.29332. Epub 2014 Nov 24.


Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group.

Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.


Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146).

Ishikawa T, Wondimu Z, Oikawa Y, Gentilcore G, Kiessling R, Egyhazi Brage S, Hansson J, Patarroyo M.

Matrix Biol. 2014 Sep;38:69-83. doi: 10.1016/j.matbio.2014.06.002. Epub 2014 Jun 18.


Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.

Azimi A, Pernemalm M, Frostvik Stolt M, Hansson J, Lehtiö J, Egyházi Brage S, Hertzman Johansson C.

Br J Cancer. 2014 May 13;110(10):2489-95. doi: 10.1038/bjc.2014.169. Epub 2014 Apr 10.


BRAF inhibitors in cancer therapy.

Hertzman Johansson C, Egyhazi Brage S.

Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8. Review.


Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.

Hjerpe E, Egyhazi Brage S, Carlson J, Frostvik Stolt M, Schedvins K, Johansson H, Shoshan M, Avall-Lundqvist E.

BMC Clin Pathol. 2013 Nov 19;13(1):30. doi: 10.1186/1472-6890-13-30.


High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma.

Falkenius J, Lundeberg J, Johansson H, Tuominen R, Frostvik-Stolt M, Hansson J, Egyhazi Brage S.

Melanoma Res. 2013 Dec;23(6):452-60. doi: 10.1097/CMR.0000000000000027.


Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.

Hertzman Johansson C, Azimi A, Frostvik Stolt M, Shojaee S, Wiberg H, Grafström E, Hansson J, Egyházi Brage S.

Melanoma Res. 2013 Oct;23(5):360-5. doi: 10.1097/CMR.0b013e328362f9cd.


Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

Zebary A, Omholt K, van Doorn R, Ghiorzo P, Harbst K, Hertzman Johansson C, Höiom V, Jönsson G, Pjanova D, Puig S, Scarra GB, Harland M, Olsson H, Egyhazi Brage S, Palmer J, Kanter-Lewensohn L, Vassilaki I, Hayward NK, Newton-Bishop J, Gruis NA, Hansson J; Melanoma Genetics Consortium (GenoMEL).

J Invest Dermatol. 2014 Jan;134(1):287-290. doi: 10.1038/jid.2013.270. Epub 2013 Jun 14. No abstract available.


Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R.

Cancer Res. 2013 Jul 1;73(13):3877-87. doi: 10.1158/0008-5472.CAN-12-4115. Epub 2013 Apr 30.

Supplemental Content

Loading ...
Support Center